| Document |
Document Title |
|
JP2004537499A |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.
|
|
JP2004534796A |
A process for the preparation of compounds of formula (I) in which R1, R2, R3 and n are defined as indicated in the description, use of said compounds as intermediates for the preparation of estrogen derivatives as well as the intermedia...
|
|
JP3590863B2 |
To provide a cholesteric liquid crystal compound that has good photorespontivity and shows high storage stability of the fixed color without acceleration of crystallization, even when it is held at room temperature after the color fixati...
|
|
JP2004534011A |
The present invention relates to steroid compounds of general formula I, which may advantageously be employed to stimulate meiosis in human oocytes, the steroid being specifically characterized by amino nitrogen bonded to C<17> of the st...
|
|
JP2004534042A |
Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding alpha,beta-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the alpha,beta-unsaturated ketone structure...
|
|
JP3581821B2 |
The present invention provides a pharmaceutical composition comprising a compound admixed with a pharmaceutically acceptable diluent or carrier; wherein the compound has the the formula wherein each of R1 and R2 is independently selected...
|
|
JP3581802B2 |
The present invention provides a pharmaceutical composition comprising a compound admixed with a pharmaceutically acceptable diluent or carrier; wherein the compound has the the formula wherein each of R1 and R2 is independently selected...
|
|
JP3581820B2 |
The present invention provides a pharmaceutical composition comprising a compound admixed with a pharmaceutically acceptable diluent or carrier; wherein the compound has the the formula wherein each of R1 and R2 is independently selected...
|
|
JP2004525945A |
The invention discloses certain steroidal sapogenins and derivatives thereof, and their use in the treatment of cognitive dysfunction, non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, and receptor loss in the ab...
|
|
JP2004523520A |
Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacy...
|
|
JP3550671B2 |
To surely impart an orienting function for liquid crystal molecules by rubbing treatment and to constitute a liquid crystal display element having excellent orientation of a liquid crystal by incorporating a specified polymer such as pol...
|
|
JP3549125B2 |
Corticoid 17,21-dicarboxylic esters and corticoid 17-carboxylic esters 21-carbonic esters of the formula I with A equal to CHOH and CHClm CH2, C=0, 9(11) double bond; Y equal to H, F, Cl; Z equal to H, F, methyl, R(1) equal to aryl, heta...
|
|
JP2004522722A |
The present invention provides a compound capable of acting as a cationic lipid, the compound comprises a cholesterol group and a carbohydrate moiety.
|
|
JP3546886B2 |
PCT No. PCT/US94/02397 Sec. 371 Date Aug. 18, 1994 Sec. 102(e) Date Aug. 18, 1994 PCT Filed Mar. 16, 1994 PCT Pub. No. WO94/20520 PCT Pub. Date Sep. 15, 1994Compounds having a broad range of antimicrobial activity generally have a struct...
|
|
JP2004521917A |
Amphoteric sterol derivatives, and liposomes containing these derivatives are new. The amphoteric sterol derivatives have an isoelectric point of 4.5-8.5 and are compounds of formula (I): Amphoter-Y-spacer-X-sterol (I) X and Y : linking ...
|
|
JP3545477B2 |
PURPOSE: To provide the subject novel derivatives, that is, specific 17- iminomethylalkenyl- and 17-iminoalkyl-14β-hydroxy-5β-androstane derivatives useful for the treatment or the like of cardiovascular diseases such as heart failure,...
|
|
JP2004520301A |
The present invention provides a compound capable of acting as a cationic lipid, the compound comprises a cholesterol group and a carbohydrate moiety.
|
|
JP2004123757A |
To obtain a sulfatase inhibitor having no estrogenic active ingredient, because a compound restricting or preventing utilization of estrogenic substances is required for hormone dependent tumors.A new estratriene of formula (I) containin...
|
|
JP3510651B2 |
PURPOSE: To provide a new compd. useful as a treating agent of cardiovascular diseases such as heart failure and hypertension, acting on cardiovascular system. CONSTITUTION: A deriv. of formula I {the dotted line shows α- or β- configu...
|
|
JP3509812B2 |
To provide an electrochemiluminescence label and an assay using the same. An agent which emits electromagnetic radiation when receiving electrochemical energy is bonded to the object of analysis, and the electrochemical energy is generat...
|
|
JP2004508364A |
Novel acid-sensitive compounds comprising at least one hydrophilic substituent and a cyclic ortho-ester which is acid-sensitive, and their salts. These compounds are useful for forming conjugates (liposomes, complexes, nanoparticles and ...
|
|
JP2004506599A |
This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and allevi...
|
|
JP2004505012A |
Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline com...
|
|
JP2004504359A |
A liver-targeting active compound having the general formula (I): wherein A is alpha-OH or beta-OH, B is alpha-H or beta-H, C is -H, alpha-OH or beta-OH, or B and C together form a double bond, D is -H, alpha-OH or beta-OH, E is -H, alph...
|
|
JP3492717B2 |
PURPOSE: To efficiently obtain the compd. useful for an intermediate of medicines or the like at high yield by bringing a compd. obtd. by oxidizing a specified compd. in the presence of water to solvolysis reaction in an acidic medium or...
|
|
JP3486411B2 |
An improved method of determining the amount of estradiol in a fluid sample and a respective kit therefore is disclosed. In particular, the invention discloses specific pretreatment conditions improving the accuracy of estradiol assays c...
|
|
JPWO2001081364A1 |
Formula (I) [In the formula, R1 and R2 are the same or different, and represent hydrogen or lower alkyl, etc., R3 represents hydrogen, etc., R4 represents hydrogen, etc., R5 represents hydrogen, etc., R6 represents cyano, etc. Estra-1,3,...
|
|
JP3476679B2 |
To safely and inexpensively detect the presence of the analyte in a sample with high sensitivity by detecting the electromagnetic radiation emitted from a reagent to which a constant quantity of electrochemical energy is applied. When a ...
|
|
JP3476157B2 |
PURPOSE: To provide the subject new compound having an activity to inhibit absorption of bile acid in the small intestine and useful as a lipid level lowering agent to lower the level of cholesterol and the like by reacting bile acid wit...
|
|
JP2003534350A |
Nonsolvated crystalline 11beta -(4-((E)-hydroxyiminomethyl)phenyl)-17alpha -methoxymethyl-17beta -methoxy-4,9-estradien-3-one (I) is new. An independent claim is also included for a process for preparing (I). ACTIVITY : Gynecological. ME...
|
|
JP2003534386A |
The invention relates to compounds which, acting as a prodrug and/or support, enable an active agent to be taken up by the erythrocytes and/or an active agent to bind to the erythrocytes. The uptake of these compounds by and/or the bindi...
|
|
JP3466651B2 |
PURPOSE: To obtain a new steroid which contains a methylene lactone group on 17-th position, which shows various hormonal activities and antihormonal activities and which is useful as a therapeutic drug for prostatic hyperfrophy, virilis...
|
|
JP2003532737A |
Compounds of formula (I) in which: R<1> represents a hydrogen atom or an O-protecting group; R<2> represents a hydroxyl, lower alkoxy, carboxaldehyde, lower alk-1-enyl or hydroxy- or lower alkoxy-substituted lower alkyl group; R<3> repre...
|
|
JP3462515B2 |
PURPOSE: To obtain the subject new compounds that have notable affinity to progesterone receptors, have little affinity to mineral corticoids, and are useful as drugs contg. anti-progestin activity having improved selectivity. CONSTITUTI...
|
|
JP2003532737A5 |
|
|
JP2003531916A |
A compound of the formula: and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein R groups are as defined by the present specification. The compounds may be formulated int...
|
|
JP2003531148A |
An efficient method for the synthesis of aminosterol compounds such as squalamine and compound 1436 is described. A method of the invention provides for regioselective sulfonation of a fused ring system. The fused ring system base can be...
|
|
JP2003530329A |
Many compounds have poor bioavailability or variable bioavailability because of poor absorption of the compound in the small intestine. Conjugation of the compound with bile acid to form a prodrug will increase the bioavailibility of the...
|
|
JP3445271B2 |
Compounds of formula (I), wherein R17 and R'17 are such that: either R17 and R'17 together form ketone, hydrazono, oxime or methylene, or R17 is hydroxyl, hydroxymethyl or acyloxy and R'17 is hydrogen, alkyl or optionally substitued alke...
|
|
JP2003238413A |
To provide a steroid sulfatase inhibitor containing a thiophosphate derivative or its pharmacologically permissible salt as an active component.The steroid sulfatase inhibitor contains a thiophosphate derivative of formula (I) (R1 and R2...
|
|
JP2003522728A |
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
|
|
JP2003192693A |
To provide a new steroid derivative having surface activity.The steroid derivative is expressed by general formula (1) (R1 and R2 are each independently a (substituted) cyclopentanoperhydrophenanthrene skeleton; and R3 is a bivalent carb...
|
|
JP2003520846A |
The present invention is directed to a compound having the structure (I): and acceptable salts, polypeptides, and pro-forms thereof, wherein R is selected from the group consisting of: (a) substituted glycerols; wherein n is an integer f...
|
|
JP3424978B2 |
PURPOSE: To obtain a new compound usuful as a drug effective as hypolipidemic medicine with a small amount which suppress the bile acid absorption concentration-dependently and antagonistically, and has high affinity for the peculiar bil...
|
|
JP3424930B2 |
An N-acylglutamine derivative represented by general formula (I). It is well compatible with oleaginous materials and excellent in humectant and hair-growth promoter effects, thus being useful as cosmetics, hair-growth promoter, and the ...
|
|
JP2003176297A |
To provide a pharmaceutical composition which is effective on the treatments of estrogen-dependent tumors.This pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a compound which contains a ring sys...
|
|
JP3418428B2 |
PURPOSE: To provide the novel steroid compounds whose steroid skeleton is bound at carbon atom 17 to a spiromethylene ring having progestational activity and antiprogenstational activities, and useful as contraceptive medicines. CONSTITU...
|
|
JP2003519176A |
Use of certain nitrate ester compounds or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating pain or providing analgesia.
|
|
JP2003517472A |
The invention concerns a 3-methylene steroid derivative having general formula (1) wherein R1 is H or together with R3 forms a beta-epoxide or R1 is absent if there is a 5-10 or 4-5 double bond; R2 is (C1-C5) alkyl or CF3; R3 is betaH, b...
|
|
JP2003517001A |
The invention relates to novel 11- beta -phenylestradiene derivatives with fluoroalkyl groups in the aromatic side chain, of general formula (I), to a method for producing them and to pharmaceutical preparations containing these compound...
|
